IBDEI2TS ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,45067,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45067,1,3,0)
 ;;=3^Sezary Disease,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,45067,1,4,0)
 ;;=4^C84.19
 ;;^UTILITY(U,$J,358.3,45067,2)
 ;;=^5001640
 ;;^UTILITY(U,$J,358.3,45068,0)
 ;;=C84.13^^170^2245^29
 ;;^UTILITY(U,$J,358.3,45068,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45068,1,3,0)
 ;;=3^Sezary Disease,Intra-Abdominal Lymph Nodes
 ;;^UTILITY(U,$J,358.3,45068,1,4,0)
 ;;=4^C84.13
 ;;^UTILITY(U,$J,358.3,45068,2)
 ;;=^5001634
 ;;^UTILITY(U,$J,358.3,45069,0)
 ;;=C84.16^^170^2245^30
 ;;^UTILITY(U,$J,358.3,45069,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45069,1,3,0)
 ;;=3^Sezary Disease,Intrapelvic Lymph Nodes
 ;;^UTILITY(U,$J,358.3,45069,1,4,0)
 ;;=4^C84.16
 ;;^UTILITY(U,$J,358.3,45069,2)
 ;;=^5001637
 ;;^UTILITY(U,$J,358.3,45070,0)
 ;;=C84.12^^170^2245^31
 ;;^UTILITY(U,$J,358.3,45070,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45070,1,3,0)
 ;;=3^Sezary Disease,Intrathoracic Lymph Nodes
 ;;^UTILITY(U,$J,358.3,45070,1,4,0)
 ;;=4^C84.12
 ;;^UTILITY(U,$J,358.3,45070,2)
 ;;=^5001633
 ;;^UTILITY(U,$J,358.3,45071,0)
 ;;=C84.14^^170^2245^25
 ;;^UTILITY(U,$J,358.3,45071,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45071,1,3,0)
 ;;=3^Sezary Disease,Axilla/Upper Limb Lymph Nodes
 ;;^UTILITY(U,$J,358.3,45071,1,4,0)
 ;;=4^C84.14
 ;;^UTILITY(U,$J,358.3,45071,2)
 ;;=^5001635
 ;;^UTILITY(U,$J,358.3,45072,0)
 ;;=C84.11^^170^2245^27
 ;;^UTILITY(U,$J,358.3,45072,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45072,1,3,0)
 ;;=3^Sezary Disease,Head/Face/Neck Lymph Nodes
 ;;^UTILITY(U,$J,358.3,45072,1,4,0)
 ;;=4^C84.11
 ;;^UTILITY(U,$J,358.3,45072,2)
 ;;=^5001632
 ;;^UTILITY(U,$J,358.3,45073,0)
 ;;=C84.15^^170^2245^28
 ;;^UTILITY(U,$J,358.3,45073,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45073,1,3,0)
 ;;=3^Sezary Disease,Inguinal Region/LE Lymph Nodes
 ;;^UTILITY(U,$J,358.3,45073,1,4,0)
 ;;=4^C84.15
 ;;^UTILITY(U,$J,358.3,45073,2)
 ;;=^5001636
 ;;^UTILITY(U,$J,358.3,45074,0)
 ;;=C84.18^^170^2245^32
 ;;^UTILITY(U,$J,358.3,45074,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45074,1,3,0)
 ;;=3^Sezary Disease,Multiple Site Lymph Nodes
 ;;^UTILITY(U,$J,358.3,45074,1,4,0)
 ;;=4^C84.18
 ;;^UTILITY(U,$J,358.3,45074,2)
 ;;=^5001639
 ;;^UTILITY(U,$J,358.3,45075,0)
 ;;=C84.17^^170^2245^33
 ;;^UTILITY(U,$J,358.3,45075,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45075,1,3,0)
 ;;=3^Sezary Disease,Spleen
 ;;^UTILITY(U,$J,358.3,45075,1,4,0)
 ;;=4^C84.17
 ;;^UTILITY(U,$J,358.3,45075,2)
 ;;=^5001638
 ;;^UTILITY(U,$J,358.3,45076,0)
 ;;=C84.10^^170^2245^34
 ;;^UTILITY(U,$J,358.3,45076,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45076,1,3,0)
 ;;=3^Sezary Disease,Unspec Site
 ;;^UTILITY(U,$J,358.3,45076,1,4,0)
 ;;=4^C84.10
 ;;^UTILITY(U,$J,358.3,45076,2)
 ;;=^5001631
 ;;^UTILITY(U,$J,358.3,45077,0)
 ;;=A53.9^^170^2245^50
 ;;^UTILITY(U,$J,358.3,45077,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45077,1,3,0)
 ;;=3^Syphilis,Unspec
 ;;^UTILITY(U,$J,358.3,45077,1,4,0)
 ;;=4^A53.9
 ;;^UTILITY(U,$J,358.3,45077,2)
 ;;=^5000310
 ;;^UTILITY(U,$J,358.3,45078,0)
 ;;=I87.2^^170^2245^41
 ;;^UTILITY(U,$J,358.3,45078,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45078,1,3,0)
 ;;=3^Stasis Dermatitis NOS
 ;;^UTILITY(U,$J,358.3,45078,1,4,0)
 ;;=4^I87.2
 ;;^UTILITY(U,$J,358.3,45078,2)
 ;;=^5008047
 ;;^UTILITY(U,$J,358.3,45079,0)
 ;;=L90.5^^170^2245^18
 ;;^UTILITY(U,$J,358.3,45079,1,0)
 ;;=^358.31IA^4^2
